If 2 biosimilars demonstrate interchangeability (IC) with the RP through suitable models (eg.crossover 2x4), would they also be IC with each other?

Would 2 biosimilars, that have separately demonstrated interchangeability with the reference product, through adequate clinical designs (phase III trials with 2 arms, and at least three changes...

24 May 2018 8,786 3 View